This SlimTide investigation uncovers the science behind its 800 mg BHB ketone blend for weight loss and exposes critical red flags consumers must know before buying Slim Tide online.
This SlimTide investigation uncovers the science behind its 800 mg BHB ketone blend for weight loss and exposes critical red flags consumers must know before buying Slim Tide online.
Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...
Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.
Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass...
AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes...
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist
STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) -- Oban BioPharma today announced that preclinical data for OBT-676, a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, has been selected for a late-breaking presentation at the upcoming American Diabetes Association (ADA) 86th Scientific Sessions being held from June 5th-8th in New Orleans, LA. The study characterizes OBT-676 as a new molecular entity that achieves potent full agonism at the amylin and calcitonin receptors (DACRA) while simultaneously delivering partial agonism across the GLP-1, GIP, and glucagon (Triple-G) pathways. OBT-676 demonstrated significant reduction in food intake and adipose-selective weight loss in the industry-standard rat diet-induced obesity (DIO) model.
A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...
Including United's offer for Spirit customers, eBay's response to GameStop's acquisition proposal, and a new partnership between major telecom providers.Plus, a recap of May's...